Abstract
Microporous surfaces of commercially available uncemented Tilastan® implants were coated with gentamicinpalmitate. The roughness of the titanium implant surfaces remained largely intact. During the first few days, the gentamicin release was comparable to the elution of this antibiotic from commercially available PMMA bone cements. Compared to PMMA cements, the implants coated with the gentamicinpalmitate completely released the gentamicin within the first five to eight days. Both uncemented implants with a gentamicinpalmitate coating and gentamicin containing bone cements used with cemented implants sustainably reduce the infection risk. It can be hypothesised that these in-vitro results are transferrable to the well documented clinical findings of antibiotic loaded cemented arthroplasty, and can therefore potentially provide a significant contribution to the reduction of infection in the use of uncemented prostheses.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
